Lates News

Novo Nordisk (NVO.N): The adjusted sales for the second quarter of 2026 were 78.49 billion Danish kroner; the adjusted operating profit was 33.39 billion Danish kroner. In the second quarter of 2026, a one-time, non-cash impairment charge of 6.3 billion Danish kroner related to intangible asset pipeline matters was recognized.